30 results about "Leukemic Stem Cell" patented technology

The invention provides a test method for predicting the initial onset or a recurrence of acute myeloid leukemia (AML) comprising (1) measuring the expression level of human leukemic stem cell (LSC) marker genes in a biological sample collected from a subject for a transcription product or translation product of the gene as an analyte and (2) comparing the expression level with a reference value; an LSC-targeting therapeutic agent for AML capable of suppressing the expression of a gene selected from among LSC marker genes or a substance capable of suppressing the activity of a translation product of the gene; a method for producing a sample containing hematopoietic cells for autologous transplantation or allogeneic transplantation for AML patients comprising obtaining an LSC-purged sample with at least 1 kind of LSC marker as an index; and a method of preventing or treating AML.

The present invention is directed to an in vitro cultured permissive niche, or human bone marrow microenvironment, comprising a scaffold coated with human mesenchymal stem cells and a culture medium, wherein the stem cells are viable and proliferate in culture and the niche is permissive for the establishment of introduced hematopoietic or leukemic cell populations. The present invention is also directed to establishment of a permissive niche in a non-human animal model comprising a scaffold coated with human mesenchymal stem cells introduced into the animal ectopically, wherein the niche and the model are permissive for the establishment of introduced hematopoietic or leukemic cell populations. The implanted scaffold forms an ectopic human bone marrow microenvironment to study the mesenchymal leukemic stem cell niche. In addition, the present invention is directed to methods of using the in vitro cultured human bone marrow microenvironment and the non-human animal model to evaluate an agent for anti-leukemic properties.

A method for inhibition of leukemic stem cells expressing IL-3Rα; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3Rα (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.

Isolated populations of leukemic stem cells are provided. The cells are useful for experimental evaluation, and as a source of lineage and cell specific products, and as targets for the discovery of factors or molecules that can affect them. Detection of leukemic stem cells is useful in predicting disease progression, relapse, and development of drug resistance. Proliferation of LSC may be inhibited through interfering with activation of the beatenin pathway. Methods are provided for the clinical staging of pre-leukemia and leukemias by differential analysis of hematologic samples for the distribution of one or more hematopoietic stem or progenitor cell subsets.

The present invention provides methods and compositions for identifying leukemic stem cells.

The present invention relates to a method for identifying Leukemic stem cells (LSC), based on measurement of the presence of a specific set of markers. The invention further relates to a container for use in performing the method. Also provided is application of the method for predicting response to therapy and/or chance of relapse of Acute Myeloid Leukemia, and application of the method in the context of screening for compounds that specifically eradicate Leukemic cells and not benign cells.

The invention relates to a method of selectively expanding human leukemic cells in a non-adult NOD/SCID/IL2rg^null mouse by transplanting a substance containing a leukemic stem cell derived from a human acute myelogenous leukemia patient to the mouse. In addition, the invention relates to screening for a medicament capable of eradicating leukemic stem cell (LSC), consideration of treatment methods suitable for individual patients, identification of a differentially expressed gene and the like, using a mouse with expanded human leukemic cells.

The invention provides a method for leukaemia high-flux medicine screening. The method comprises the following steps of performing separation, extraction, identification and culture on neoplastic hematologic disorder stem cells: performing acquisition on bone marrow samples, performing separation on mononuclear cells, performing separation on leukaemia stem cell groups through an immunomagnetic bead method; and performing subculturing on the cells after separation and purification of magnetic beads; and establishing a medicine library: according to a medicine description and pharmacokinetics,selecting the concentration of medicines, performing mixed culture on the medicines and the neoplastic hematologic disorder stem cells, and analyzing the restraining effect of the medicines on the neoplastic hematologic disorder stem cells. According to the method for leukaemia high-flux medicine screening disclosed by the invention, in accordance with a patient, an appropriate treatment scheme and opinions can be accurately given in an individualizing manner, a valuable treatment opportunity is strived for the recurrent and refractory patient, reagent risk is reduced, the medicine curative effect is increased to the maximum degree, and medicine side effects are reduced to the maximum degree; and besides, pharmaceutical combinations can be performed, in accordance with clinical frequently-used chemotherapeutics combinations, comprehensive marking is performed, and a reference is provided for a doctor in the respect of formulating clinical united medication for the patient.

A method for treating a leukemia patient that is resistant to a thymidine kinase inhibitor (TKI) other than imantinib comprising administering a cephalotaxine to said patient until said patient demonstrates a hematological or cytological response to said leukemia.

The present invention relates to diagnostic screens, gene expression profiles, methods and kits for detection of acute myeloid leukaemia leukaemic stem cells. Diagnostic and prognostic methods based on said diagnostic screens and/or gene expression profiles also form part of the invention.

Using the cobblestone area (CA) formation inhibitory activity of human leukemic stem cell-like cells as an indicator, a fraction having the activity has been extracted from the fat-soluble fraction of Porifera, then, a compound having the activity has been isolated and purified from the aforementioned fraction, and then, the structure thereof has been determined, so that a Stelliferin compound comprising a novel compound has been identified. Moreover, it has been found that the isolated and purified Stelliferin compound significantly suppresses the niche formation of leukemic stem cell-like cells derived from human chronic myelogenous leukemia (CML) having resistance to existing antitumor agents and enhances the effects of antitumor agents on the cells. The present invention provides a pharmaceutical composition having inhibitory or suppressive activity against the niche formation of leukemic stem cells, a prophylactic agent against the recurrence of malignant tumor, which involves the combined use of other antitumor drugs, and the like.